ACIU AC Immune SA

3,697

$3.31

$0.10

(3.12%)

Today

Watchers	3,697
52-Wk Low	$1.68
52-Wk High	$3.83

Market Cap	$288.39M
Volume (M)	223.00
52-Wk High	$3.83
52-Wk Low	$1.68

Fundamentals

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOGlobe Newswire • about 2 hours ago

AC Immune appoints Madiha Derouazi as CSO Dr. Madiha Derouazi appointed as new CSO of AC Immune AC Immune appoints Christopher Roberts as CFO Christopher...

Share to Feed

AC Immune SA (ACIU, $3.21) Stochastic Oscillator left the overbought zone on November 29, 2023Tickeron - Stocks • 1 day ago

This is a signal that ACIU's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

AC Immune SA (ACIU, $3.03) Stochastic Oscillator left the overbought zone on November 22, 2023Tickeron - Technical Analysis • 8 days ago

This is a signal that ACIU's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

AC Immune SA (ACIU, $3.19) price may drop as it broke higher Bollinger Band on Nov 20, 2023Tickeron - Technical Analysis • 10 days ago

This price move could be a signal that ACIU may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Promising Outlook for AC Immune SA: Buy Rating Based on Potential Alzheimer Trials Success and Encouraging ABATE Study ProgressTipRanks Financial Blog • 18 days ago

AC Immune SA (ACIU Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. W...

AC Immune to Present at the Jefferies 2023 London Healthcare ConferenceGlobe Newswire • 24 days ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateGlobe Newswire • 28 days ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023Globe Newswire • 29 days ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 AC Immune SA...

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease DiagnosticGlobe Newswire • about 1 month ago

PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the...

AC Immune Announces Upcoming Presentations at the 16th CTAD ConferenceGlobe Newswire • about 2 months ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...